2型糖尿病患者患膀胱癌的风险：立陶宛一项基于人群的回顾性队列研究。

Risk of bladder cancer in patients with type 2 diabetes mellitus: a retrospective population-based cohort study in Lithuania.

作者信息

Ladukas Adomas, Patasius Ausvydas, Kincius Marius, Drevinskaite Mingaile, Jonusas Justinas, Linkeviciute-Ulinskiene Donata, Zabuliene Lina, Smailyte Giedre

机构信息

Laboratory of Cancer Epidemiology, National Cancer Institute, 1 Santariskiu St, 08406, Vilnius, Lithuania.

Department of Public Health, Institute of Health Sciences, Faculty of Medicine, Vilnius University, 21/27 M. K. Ciurlionio St, 03101, Vilnius, Lithuania.

出版信息

Cancer Causes Control. 2025 Jan;36(1):21-25. doi: 10.1007/s10552-024-01911-2. Epub 2024 Sep 21.

DOI:10.1007/s10552-024-01911-2

PMID:39305342

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11761827/

Abstract

PURPOSE

The objective of our study was to evaluate bladder cancer risk among Lithuanian type 2 diabetes mellitus (T2DM) patients and the effect of antihyperglycemic therapy on bladder cancer risk.

METHODS

We analyzed bladder cancer risk in a cohort of patients who were diagnosed with T2DM between 2001 and 2012 in Lithuania. Bladder cancer risk in four groups of antihyperglycemic medication users (insulin-only, metformin-only, sulfonylurea-only, and pioglitazone ± any other drug) was also assessed. Standardized incidence ratios for bladder cancer were calculated.

RESULTS

A total of 76,818 patients (28,762 males and 48,056 females) with T2DM were included in the final cohort. In the whole cohort of diabetic patients, 277 bladder cancer cases were observed, compared to 232.75 expected cases, according to bladder cancer rates in the general population (Standardized Incidence Ratio 1.19; 95% Confidence Interval: 1.06-1.34). Higher risk of bladder cancer was found in both men and women; however, in women the risk increase was not statistically significant. We found higher risk of bladder cancer in patients of both sexes diagnosed with T2DM at the age of 50-79 years and also in all groups of different antihyperglycemic medication users.

CONCLUSION

T2DM was associated with increased risk of bladder cancer.

摘要

目的

我们研究的目的是评估立陶宛2型糖尿病（T2DM）患者患膀胱癌的风险以及降糖治疗对膀胱癌风险的影响。

方法

我们分析了2001年至2012年在立陶宛被诊断为T2DM的患者队列中的膀胱癌风险。还评估了四组降糖药物使用者（仅使用胰岛素、仅使用二甲双胍、仅使用磺脲类药物以及使用吡格列酮±任何其他药物）的膀胱癌风险。计算了膀胱癌的标准化发病率。

结果

最终队列纳入了总共76,818例T2DM患者（男性28,762例，女性48,056例）。在整个糖尿病患者队列中，观察到277例膀胱癌病例，而根据一般人群的膀胱癌发病率，预期病例数为232.75例（标准化发病率1.19；95%置信区间：1.06 - 1.34）。男性和女性患膀胱癌的风险均较高；然而，女性的风险增加在统计学上不显著。我们发现50 - 79岁被诊断为T2DM的男女患者以及所有不同降糖药物使用者组患膀胱癌的风险都较高。